While safety and indication of biological effect in HIV-infected individuals have been observed for delivery to CD4+T cells [17]–[24] and to CD34+ HSC [25]–[29], the clinical impact of each cellular target in terms of long-term preservation of total CD4+T cell counts and forestalment of AIDS remains uncertain. The gene discussed is CD4; the disease is AIDS.